Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

Published:2019-04-23 Issue:4 Volume:48 Page:266-270
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

l’ Ami MJ¹,Ruwaard J¹,Krieckaert CLM¹,Nurmohamed MT¹²,van Vollenhoven RF¹²³,Rispens T⁴,Wolbink GJ¹⁴

Affiliation:

1. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands

2. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, UMC/VU University Medical Center, Amsterdam, The Netherlands

3. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, UMC/Academic Medical Center, Amsterdam, The Netherlands

4. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, The Netherlands

Funder

AbbVie

Novartis

Sanofi

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2019.1577915

Reference14 articles.

1. Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

3. Key findings towards optimising adalimumab treatment: the concentration–effect curve

4. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis

5. Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication;Therapeutic Drug Monitoring;2024-01-24

2. Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study;The Journal of Rheumatology;2024-01-15

3. Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial;Scandinavian Journal of Rheumatology;2022-10-31

4. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06

5. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases;Annals of the Rheumatic Diseases;2022-05-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3